156 related articles for article (PubMed ID: 36762110)
1. Binding and functional structure-activity similarities of 4-substituted 2,5-dimethoxyphenyl isopropylamine analogues at 5-HT
Hemanth P; Nistala P; Nguyen VT; Eltit JM; Glennon RA; Dukat M
Front Pharmacol; 2023; 14():1101290. PubMed ID: 36762110
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
Nelson DL; Lucaites VL; Wainscott DB; Glennon RA
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):1-6. PubMed ID: 9933142
[TBL] [Abstract][Full Text] [Related]
3. Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands.
Canal CE; Cordova-Sintjago T; Liu Y; Kim MS; Morgan D; Booth RG
J Pharmacol Exp Ther; 2013 Dec; 347(3):705-16. PubMed ID: 24080681
[TBL] [Abstract][Full Text] [Related]
4. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
5. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
[TBL] [Abstract][Full Text] [Related]
6. Effect of Bulky
Soares BA; Yempala T; Martínez-Afani D; Acevedo-Fuentes W; Brea J; Loza MI; Cimadevila M; Cassels BK
ACS Chem Neurosci; 2024 Feb; 15(3):608-616. PubMed ID: 38241462
[TBL] [Abstract][Full Text] [Related]
7. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
Cussac D; Newman-Tancredi A; Quentric Y; Carpentier N; Poissonnet G; Parmentier JG; Goldstein S; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Mar; 365(3):242-52. PubMed ID: 11882920
[TBL] [Abstract][Full Text] [Related]
8. Cervical spinal 5-HT
Tadjalli A; Mitchell GS
J Appl Physiol (1985); 2019 Aug; 127(2):432-443. PubMed ID: 31219768
[TBL] [Abstract][Full Text] [Related]
9. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
[TBL] [Abstract][Full Text] [Related]
10. Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT
Pottie E; Poulie CBM; Simon IA; Harpsøe K; D'Andrea L; Komarov IV; Gloriam DE; Jensen AA; Kristensen JL; Stove CP
ACS Chem Neurosci; 2023 Aug; 14(15):2727-2742. PubMed ID: 37474114
[TBL] [Abstract][Full Text] [Related]
11. N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues.
Nichols DE; Sassano MF; Halberstadt AL; Klein LM; Brandt SD; Elliott SP; Fiedler WJ
ACS Chem Neurosci; 2015 Jul; 6(7):1165-75. PubMed ID: 25547199
[TBL] [Abstract][Full Text] [Related]
12. Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines.
Kolaczynska KE; Luethi D; Trachsel D; Hoener MC; Liechti ME
Front Pharmacol; 2019; 10():1423. PubMed ID: 31849671
[No Abstract] [Full Text] [Related]
13. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
[TBL] [Abstract][Full Text] [Related]
14. Molecular and pharmacological characterization of serotonin 5-HT2A and 5-HT2B receptor subtypes in dog.
Bonaventure P; Nepomuceno D; Miller K; Chen J; Kuei C; Kamme F; Tran DT; Lovenberg TW; Liu C
Eur J Pharmacol; 2005 Apr; 513(3):181-92. PubMed ID: 15862800
[TBL] [Abstract][Full Text] [Related]
15. A new class of 5-HT
Casey AB; Mukherjee M; McGlynn RP; Cui M; Kohut SJ; Booth RG
Br J Pharmacol; 2022 Jun; 179(11):2610-2630. PubMed ID: 34837227
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists.
Hansen M; Jacobsen SE; Plunkett S; Liebscher GE; McCorvy JD; Bräuner-Osborne H; Kristensen JL
Bioorg Med Chem; 2015 Jul; 23(14):3933-7. PubMed ID: 25583099
[TBL] [Abstract][Full Text] [Related]
17. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs).
Rickli A; Luethi D; Reinisch J; Buchy D; Hoener MC; Liechti ME
Neuropharmacology; 2015 Dec; 99():546-53. PubMed ID: 26318099
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.
Porter RH; Benwell KR; Lamb H; Malcolm CS; Allen NH; Revell DF; Adams DR; Sheardown MJ
Br J Pharmacol; 1999 Sep; 128(1):13-20. PubMed ID: 10498829
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
